Cynata Therapeutics : 14.10.23.Cynata to Appoint Dr John Chiplin to Board of Directors

Cynata Therapeutics Ltd (ASX:CYP)is delighted to announce that highly regarded life sciences and technology industry executive Dr John Chiplin is to join the Company's Board of Directors as an Independent Non-Executive Director.
Dr Chiplin has significant international experience in the life science and technology industries, from both an operational and investment perspective. Recent transactions that Dr Chiplin has been involved in include US stem cell company Medistem (acquired by Intrexon), Arana (acquired by Cephalon), and Domantis (acquired by GlaxoSmithKline). Prior to his role at Arana, Dr Chiplin was head of the $300M ITI Life Sciences investment fund in the UK and his own investment vehicle, Newstar Ventures Ltd, has funded more than a dozen early stage companies in the past ten years. Dr Chiplin is a Director of Benitec Biopharma (ASX: BLT) and also serves on the boards of Adalta Pty Ltd and ScienceMedia, Inc. His Pharmacy and Doctoral degrees are from the University of Nottingham, UK.
Dr Chiplin commented "Cynata's Cymerus™ platform represents a genuine and unique breakthrough in stem cell technology. I believe its broad applicability in the field will lead to substantial commercial success. I am delighted to join Cynata at this very exciting time for the company and for regenerative medicine." Dr Stewart Washer, Cynata's Executive Chairman, welcomed Dr Chiplin's decision to join the Board and noted "John's broad exposure to international equity capital markets and his direct experience in a number of very successful corporate transactions, including the recent sale of Medistem, is particularly relevant to Cynata's current partnership discussions. Importantly, his San Diego base places John in the centre of one of the most productive development and investment hubs for regenerative medicine."
Dr Chiplin will formally join the Cynata board following the Company's Annual General Meeting on
18 November 2014.
As part of the re-alignment of the Board, Mr Howard Digby will step down from his role as a Non-Executive Director. Dr Washer thanked Mr Digby and noted "On behalf of the Board I express our gratitude to Howard for his significant contributions to Cynata and particularly in his stewardship during the acquisition of Cynata Inc last year. We wish him success in the future."

North, Victoria 3122 T: + 613 9824 5254 F: + 613 9822 7735 E: adm in@cynata.com

W: www.cynata.comABN - 98 104 037 372

Media contacts: Dr Ross Macdonald, CEO: Tel: 0412 119343;email ross.macdonald@cynata.com

Dr Stewart Washer, Executive Chairman: Tel: 0418 288212; email stewart.washer@cynata.com

Cynata Therapeutics Ltd (ASX: CYP) is an Australian stem cell and regenerative medicine company that is developing a therapeutic stem cell platform technology, Cymerus™, originating from the University of Wisconsin-Madison, a world leader in stem cell research. The proprietary Cymerus™ technology seeks to address a critical shortcoming in existing methods of production of mesenchymal stem cells (MSCs) for therapeutic use, which is the ability to achieve economic manufacture at commercial scale. Cymerus™ does so through the production of a particular type of MSC precursor, called a mesenchymoangioblast (MCA). The Cymerus™ MCA platform provides a source of MSCs that is independent of donor limitations and provides a potential "off-the-shelf" stem cell platform for therapeutic product use, with a pharmaceutical business model and economies of scale. This has the potential to create a new standard in the emergent arena of stem cell therapeutics and provides both a unique differentiator and an important competitive position.

North, Victoria 3122 T: + 613 9824 5254 F: + 613 9822 7735 E: adm in@cynata.com

W: www.cynata.comABN - 98 104 037 372

distributed by